BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Treatment
27507 results:

  • 1. Risk factor analysis and nomogram development and verification for medullary carcinoma of the colon using SEER database.
    Yang L; Yu L; Zhou Q; Liu L; Shen N; Li N
    Sci Rep; 2024 May; 14(1):11426. PubMed ID: 38763982
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
    Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
    Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
    Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
    J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Knockdown of trem2 promotes proinflammatory microglia and inhibits glioma progression via the JAK2/STAT3 and NF-κB pathways.
    Yan Y; Bai S; Han H; Dai J; Niu L; Wang H; Dong Q; Yin H; Yuan G; Pan Y
    Cell Commun Signal; 2024 May; 22(1):272. PubMed ID: 38750472
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
    Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
    PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Prognostic nomogram in middle-aged and elderly patients with chordoma: A SEER-based study.
    Ouyang C; Sun Y; Li Y; Jiang M; Nong L; Gao G
    J Orthop Surg (Hong Kong); 2024; 32(2):10225536241254208. PubMed ID: 38744697
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (germELATOX-A): the doctors' perspective.
    Kähler KC; Gutzmer R; Angela Y; Livingstone E; Lodde G; Meiss F; Rafei-Shamsabadi DA; Weyer-Fahlbusch SS; Nashan D; Loquai C; Hassel JC; Sachse MMM; Maul LV; Heinzerling L; Heppt MV; Colapietro C; Rusch J; Blome C
    J Cancer Res Clin Oncol; 2024 May; 150(5):252. PubMed ID: 38743104
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. PPAR-γ agonists reactivate the ALDOC-NR2F1 axis to enhance sensitivity to temozolomide and suppress glioblastoma progression.
    Chang YC; Chan MH; Li CH; Chen CL; Tsai WC; Hsiao M
    Cell Commun Signal; 2024 May; 22(1):266. PubMed ID: 38741139
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Association of 5-aminolevulinic acid fluorescence guided resection with photodynamic therapy in recurrent glioblastoma: a matched cohort study.
    da Silva EB; Vasquez MWM; de Almeida Teixeira BC; Neto MC; Sprenger F; Filho JLN; Almeida-Lopes L; Ramina R
    Acta Neurochir (Wien); 2024 May; 166(1):212. PubMed ID: 38739282
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. [A rare cause of hypercorticism: ACTH-secreting pheochromocytoma (a case report)].
    Rifai K; Toulali F; Iraqi H; Ettaik M; Gharbi MEH
    Pan Afr Med J; 2024; 47():88. PubMed ID: 38737225
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. In Vitro and In Vivo Studies of Melanoma cell Migration by Antagonistic Mimetics of Adhesion Molecule L1CAM.
    Pompili SVB; Fanzini S; Schachner M; Chen S
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732030
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. EGCG Disrupts the LIN28B/Let-7 Interaction and Reduces Neuroblastoma Aggressiveness.
    Cocchi S; Greco V; Sidarovich V; Vigna J; Broso F; Corallo D; Zasso J; Re A; Rosatti EF; Longhi S; Defant A; Ladu F; Sanna V; Adami V; D'Agostino VG; Sturlese M; Sechi M; Aveic S; Mancini I; Sighel D; Quattrone A
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732012
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Repeat Radiosurgery for Sporadic Vestibular Schwannoma After Primary Radiosurgical Failure: An International Multi-institutional Investigation.
    Khandalavala KR; Herberg HA; Kay-Rivest E; Moore LS; Yancey KL; Marinelli JP; Lund-Johansen M; Kosaraju N; Lohse CM; Kutz W; Santa Maria PL; Golfinos JG; Kondziolka D; Carlson ML; Tveiten ØV; Link MJ
    Otol Neurotol; 2024 Jun; 45(5):587-593. PubMed ID: 38728563
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Targeting Integrin α3 Blocks β1 Maturation, Triggers Endoplasmic Reticulum Stress, and Sensitizes Glioblastoma cells to TRAIL-Mediated Apoptosis.
    Kuranaga Y; Yu B; Osuka S; Zhang H; Devi NS; Bae S; Van Meir EG
    Cells; 2024 Apr; 13(9):. PubMed ID: 38727288
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Vaccimel immunization is associated with enhanced response to treatment with anti-PD-1 monoclonal antibodies in cutaneous melanoma patients - a case reports study.
    Mordoh J; Schwab E; Bravo AI; Aris M; Barrio MM
    Front Immunol; 2024; 15():1354710. PubMed ID: 38726010
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
    Schadendorf D; Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Yamazaki N; Queirolo P; Guenzel C; Polli A; Thakur M; di Pietro A; Ascierto PA
    Eur J Cancer; 2024 Jun; 204():114073. PubMed ID: 38723373
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
    Moser JC; Bhatia S; Amin A; Pavlick AC; Betts KA; Du EX; Poretta T; Shelley K; Srinivasan S; Sakkal LA; Palaia J; Lobo M; Pe Benito M; Linton JA; Chen Y; Xu C; Yin L; Sundar M; Weber J
    Cancer Immunol Immunother; 2024 May; 73(7):116. PubMed ID: 38713408
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Total hysterectomy versus radical hysterectomy in neuroendocrine cervical cancer: a SEER-database analysis.
    Zeng F; Guo P; Xia M; He M
    J Cancer Res Clin Oncol; 2024 May; 150(5):236. PubMed ID: 38710946
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Understanding the Association Between Social Determinants of Health and Receipt of Immunotherapy for Melanoma.
    Ramirez F; Vasquez R; Gill J; Riva H; Zambrano A; Samaniego M; Fernandez L; Chacon J
    J Drugs Dermatol; 2024 May; 23(5):311-315. PubMed ID: 38709695
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Metastatic Merkel cell Carcinoma After Simultaneous Pancreas-Kidney Transplantation: Fatal Outcomes.
    Burke O; Labib A; Burke G; Beer J; Nichols A
    J Drugs Dermatol; 2024 May; 23(5):376-379. PubMed ID: 38709686
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 1376.